What is antral gastritis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Antral Gastritis?

Antral gastritis is chronic inflammation of the gastric antrum (the lower portion of the stomach near the pylorus) that is most commonly caused by Helicobacter pylori infection and represents the initial stage of what can progress to atrophic gastritis with intestinal metaplasia. 1

Pathophysiology and Anatomic Distribution

Antral gastritis typically begins as inflammation in the antrum and incisura (the transitional zone between antrum and corpus). 1 In H. pylori-associated antral gastritis (HpAG), the atrophic changes arise initially in the incisura and antrocorporal transitional mucosa as small foci with loss of glands and intestinal metaplasia. 1 Over time, these foci coalesce to form larger patches of atrophic/metaplastic mucosa along the lesser curvature and antrum, eventually spreading to the corpus/fundus. 1

This anatomic pattern distinguishes HpAG from autoimmune gastritis (AIG), which characteristically shows corpus-predominant atrophy with antral sparing. 1 However, if antral atrophy is seen in a patient with otherwise corpus-predominant disease, concomitant HpAG should be considered. 1

Histopathologic Features

The diagnosis of antral gastritis must be confirmed by histopathology. 1 The inflammatory process involves:

  • Chronic inflammation with lymphocytic infiltration of the gastric mucosa 2, 3
  • Progressive glandular loss (atrophy) that develops after years of mucosal inflammation 1
  • Intestinal metaplasia (IM), which is the most frequently diagnosed histopathologic manifestation and almost invariably implies the diagnosis of atrophic gastritis 1
  • Metaplastic replacement where gastric glands may be replaced with connective tissue (nonmetaplastic atrophy) or different epithelium (metaplastic atrophy) 1

Etiology and Associated Conditions

H. pylori Infection

H. pylori is detected in approximately 90% of patients with antral gastritis and duodenal ulcer disease. 2 The organism colonizes the antral mucosa affected by chronic gastritis, and its presence is significantly correlated with grades 2 and 3 gastritis (p < 0.001). 2 Active chronic gastritis (grade 3) is seen in 65% of those with C. pylori and is not found in patients without the bacterium. 2

Association with Peptic Ulcer Disease

Chronic antral gastritis is much more commonly associated with gastric or duodenal ulcer compared to chronic body gastritis. 3 Antral gastritis has been described in up to 100% of patients with duodenal ulcer disease. 2 The natural history of chronic antral gastritis appears the same in asymptomatic individuals and patients with peptic ulcer, suggesting these conditions are involved in a common mucosal inflammatory process. 3

NSAID-Induced Gastritis

Chemical gastritis from chronic NSAID use can affect the antrum, though it is present in only a limited number of patients (approximately 9% in chronic NSAID users versus 5% in controls). 4 The presence of chemical gastritis is not strongly correlated with NSAID-induced damage, and in many cases of peptic ulcer or upper gastrointestinal bleeding in NSAID users, chemical gastritis alone cannot account for the mucosal damage. 4

Clinical Significance and Cancer Risk

The severity and topographic distribution of atrophic lesions are well-established determinants of gastric cancer risk. 1 The risk of progression from atrophic gastritis to gastric adenocarcinoma ranges from 0.1% to 0.3% per year, but may be higher depending on severity, extent, and concomitant intestinal metaplasia. 1

Extensive atrophy and metaplasia in the antrum are associated with increased gastric cancer risk, and incomplete (colonic-type) intestinal metaplasia carries a 3-fold higher cancer risk than complete type. 5

Important Clinical Pitfalls

  • Antral healing can occur at long-term follow-up, particularly after H. pylori eradication, which may cause CAG with initially documented antral involvement to mimic autoimmune gastritis over time. 6 In one study, 25.6% of patients showed complete antral healing at follow-up (mean 40.6 months), and atrophic antral gastritis regressed in 22.8% of patients. 6

  • Separate specimen jars are essential: Biopsies from the corpus and antrum/incisura must be placed in separately labeled jars to accurately assess the anatomic distribution and distinguish between HpAG and AIG. 1, 5

  • Intestinal metaplasia presence: Providers should recognize that the presence of intestinal metaplasia on gastric histology almost invariably implies the diagnosis of atrophic gastritis, requiring coordinated effort between gastroenterologists and pathologists to document extent and severity. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Etiology and management of chronic gastritis.

Digestive diseases (Basel, Switzerland), 1989

Guideline

Treatment of Antral Gastritis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Antral mucosa healing at long-term follow-up in patients with corpus atrophic gastritis and concomitant antral gastritis may mimic autoimmune gastritis.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.